

REMARKS:**Summary of Amendments**

Claims 13 and 14 have been amended and claims 15-20 have been added to more particularly define the present invention. Claim 12 has been canceled. No new matter has been added. Claims 1-11 and 13-20 are in the application.

Claim Rejection - 35 U.S.C. § 112, First Paragraph

The Examiner rejected claim 12 under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Specifically the Examiner contends that claim 12 is directed to a therapeutic method of treating tumors in general, but the specification does not teach treatment of humors in general.

Applicants have canceled claim 12, and added claims 15-17 directed a method for treating a cancer in a mammal and claims 18-20 directed to a method for inhibiting the growth of tumor cells in a mammal.

The specification of the present application describes the test procedures and test data of antiproliferative activities on the following cell lines:

KB/HeLa	cervical carcinoma
L1210	lymphocyte leukemia
MCF7	breast adenocarcinoma
SKOV-3	ovarian adenocarcinoma

Additional examples and biological test results are set forth in the Appendix attached hereto, which further illustrate the antiproliferative activities of certain compounds on the following cell lines:

SF-268	glioblastoma
NCI-H460	pulmonary carcinoma

It is respectfully submitted that new method claims 15-20 are supported by the disclosure in the application and the additional evidence submitted herewith. The claim rejection under 35 U.S.C. § 112, first paragraph, is overcome and withdrawal thereof is respectfully requested.

Conclusion

In view of the remarks and submission, favorable consideration and allowance of all of the claims now present in the application are respectfully requested.

Should the Examiner require or consider it advisable that the specification, claims and/or drawings be amended or corrected in formal respects in order to place the case in condition for allowance, then it is respectfully requested that such amendment or correction be carried out by Examiner's Amendment and the case passed to issue. Alternatively, should the Examiner feel that a personal discussion might be helpful in advancing this case to allowance, the Examiner is invited to telephone the undersigned.

The Commissioner is authorized to charge the terminal disclaimer fee, Information Disclosure Statement fee and any other required fees or credit any overpayment to Goodwin Procter LLP Deposit Account 06-0923.

Respectfully submitted for Applicants,



Eva Tan (Reg. No. 46,406)
Goodwin Procter L.L.P.
103 Eisenhower Parkway
Roseland, NJ 07068
(973) 422-7904